Intelligent Bio Solutions Inc. (INBS) partners with Syrma Johari MedTech to enhance manufacturing capacity and gross margins.
The partnership anticipates a 20% increase in gross margin ahead of INBS's U.S. market entry in 2026.
Syrma Johari's experience, scale, and quality-assurance capabilities align with INBS's global expansion plans.
Strategic Partnership
INBS collaborates with Syrma Johari MedTech to scale production and enhance supply-chain resilience.
Expected Margins Boost
The partnership aims for a 20% improvement in gross margin compared to previous arrangements.
Operational Efficiency
Anticipated annual cost savings of over 40% to drive improved financial performance.
Global Manufacturing Strength
Syrma Johari's global footprint and certifications complement INBS's growth strategy.
Regulatory Alignment
Syrma Johari's regulatory expertise supports INBS's regulatory pathways and quality standards.
- The partnership with Syrma Johari is expected to bring substantial operational and financial benefits to Intelligent Bio Solutions Inc.
- By reducing reliance on a single supplier and increasing manufacturing capacity, INBS is poised to efficiently meet future demand and expand into the U.S. market in 2026.
- Syrma Johari's expertise in regulated medical device manufacturing and expanding capabilities will enhance product quality and cost efficiency for INBS.
The collaboration with Syrma Johari MedTech marks a significant milestone for INBS, strengthening its manufacturing capabilities and global supply chain resilience. This strategic partnership is poised to drive growth, improve margins, and position INBS for success in the competitive medical technology market.